Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

May 8, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that Nucro-Technics Inc. ("Nucro-Technics"), a Toronto-based contract research organization collaborating with Onco on preclinical development, has commenced advanced bioanalytical work in support of the Company's ongoing non-GLP1 pharmacokinetic (PK) and biodistribution animal model study involving A83B4C63, the active...

Read more

EU Regulators Say Charlotte's Web Hemp CBD Safety "Cannot Be Established" - So Why Is It Entering Medicare?

May 8, 2026 5:20 PM

A growing conflict between international scientific findings and U.S. healthcare policy is raising urgent questions about whether Medicare beneficiaries are being exposed to cannabinoid products that have not been proven safe.In March 2026, the European Food Safety Authority (EFSA) issued a formal scientific rejection of Charlottes Web hemp product submission concluding that the safety of a carbon dioxide extract derived from Cannabis sativa L....

Read more

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026

May 8, 2026 4:30 PM

Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026.Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025...

Read more

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

May 8, 2026 11:25 AM

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research has published an updated research report raising its 2026 revenue and EPS forecasts, while reaffirming its $4.50 per share valuation.The updated report projects revenue growth from a record $65.3 million in fiscal year 2025 to $103.2 million in 2026 - up from Zacks' prior...

Read more

Experts Warn GOP: Don't Side With Hospital Lobby Over Trump 340B Reforms

May 8, 2026 10:25 AM

The Hospital Accountability Project convened a roundtable of leading health policy experts this week to examine abuse in the federal 340B Drug Pricing Program and the urgent need for reform."President Trump is pushing a reform that could prevent billions in waste, fraud, and abuse," said West Cuthbert of American Resolve Action, who moderated the May 5 roundtable discussion. "The administration is trying to bring transparency to a program that...

Read more

TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals

May 8, 2026 10:00 AM

TruMerit, a global leader in healthcare workforce development and credential verification, today announced that it has issued its first verifiable digital credentials to healthcare professionals through a new partnership with Credivera, marking a major step forward in secure, portable credential verification for the global healthcare workforce.The first group of digital credentials has been awarded to nurses and other healthcare professionals...

Read more

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

May 8, 2026 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel ("Panel") granting the Company's request for an extension to demonstrate compliance with the Nasdaq Listing Rules.As previously disclosed, on May 1, 2026, Jaguar received written notification from the...

Read more

Black Book Nurses Week Survey: Payer Delays Are Reaching the Bedside Before Hospital C-Suite Sees the Damage

May 8, 2026 8:15 AM

Black Book Research today released Payer Friction at the Bedside, the third report in its Nurses Week 2026 registered nurse survey series, warning that hospitals and payers are underestimating how deeply prior authorization, denials, discharge delays, formulary restrictions, and opaque payer decisions are affecting nurses and patients in real time.The new report, based on a survey of 119 hospital-based registered nurses conducted between...

Read more

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

May 8, 2026 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, announced that CEO, Dr. Lynn Kirkpatrick, presented as an invited speaker and was featured on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.This meeting gathered experts from...

Read more

Monthly Letter April - Increased Activity and Growing Implementations

May 8, 2026 7:45 AM

iZafe Group (STO:IZAFE-B) - April was characterized by a high level of activity across several areas. We continue to see strong interest in Dosell, both in Sweden and internationally, while the focus is increasingly shifting from procurement processes and dialogue to actual implementation and scaling.During the month, we continued to strengthen the organization in order to meet growing demand and manage an increasing number of start-ups,...

Read more

Judge Takes CMS HEMP-MARIJUANA CBD Program Under Advisement - As Evidence Mounts That Medicare May Be Moving Ahead of FDA Science

May 8, 2026 7:15 AM

The future of federal cannabinoid policy now sits with the court after Judge Trevor N. McFadden took under advisement an emergency motion to halt the Centers for Medicare & Medicaid Services' (CMS) cannabinoid access program.The case,Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.Case No. 1:26-cv-01081 (D.D.C.),challenges whether CMS exceeded its authority by allowing provider mediated furnishing of certain...

Read more

Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity

May 8, 2026 5:50 AM

Genflow (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrants for a total of 30,756,577 new ordinary shares in the capital of the Company (the "Warrant Shares") with gross proceeds amounting to £359,374.99.The Warrant Shares comprise:2,631,578 new ordinary shares being issued pursuant to the...

Read more

Dr. Andrea Joy Smith to Present Oral Conscious Sedation Lecture at Sacramento Society of the National Dental Association General Meeting

May 7, 2026 11:05 PM

Dr. Andrea Joy Smith, DDS, will serve as the featured presenter during the Sacramento Society of the National Dental Association's upcoming general meeting on May 28, 2026, where she will provide a lecture focused on oral conscious sedation.The Sacramento Society of the National Dental Association is a chapter of the National Dental Association, which supports dental professionals through education, networking, advocacy, and community...

Read more

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026 4:15 PM

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.Corporate HighlightsAnnounced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injuryReceived net proceeds of $6.7 million from...

Read more

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

May 7, 2026 4:05 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026."In the first quarter of 2026, we continued to strengthen our commercial foundation and core business, highlighted by the...

Read more

Queue Ventures Announces Results of Special Meeting of Custom Health, Inc. in Connection With Previously Announced Plan of Arrangement

May 7, 2026 12:45 PM

Queue Ventures Ltd. ("Queue" or the "Company") is pleased to announce, further to its press release dated May 1, 2026, the results of the special meeting of shareholders ("Custom Shareholders") of Custom Health, Inc. ("Custom Health") held on May 6, 2026 (the "Custom Meeting").Custom Shareholders voted in favour of the resolution to approve the Company's previously announced plan of arrangement (the "Arrangement") with Custom Health. As...

Read more

Medical Component Specialists Appoints Chris Hester as President and CEO to Drive Next Phase of Global Growth

May 7, 2026 12:30 PM

Medical Component Specialists, a premier provider of precision medical components, proudly announces that Chris Hester has joined the company as its President and Chief Executive Officer, effective April 27, 2026. Hester's appointment marks a pivotal milestone in the company's 2026 leadership team expansion and signals a vibrant era of forward momentum, capacity scaling, and international growth. A seasoned manufacturing leader and strategic...

Read more

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

May 7, 2026 11:00 AM

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market...

Read more

Medical Care Technologies Inc. (OTC PINK:MDCE) Unlocks New Applications for AI Imaging Platform in Regulated Agricultural Markets

May 7, 2026 9:15 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) ("the Company"), a developer of artificial intelligence (AI) imaging solutions, today announced it is advancing new applications of its AI imaging platform focused on improving product verification and quality control in regulated agricultural markets. As regulatory standards tighten, the Company believes there is increasing demand for scalable technologies that help ensure products are accurately...

Read more

CVS Health's Annual Impact in Connecticut

May 7, 2026 9:00 AM

Originally published in the CVS Health National Economic Impact ReportWith more than 9,000 locations and 300,000 employees, CVS Health is a driving force in the American economy, delivering $474 billion in economic impact nationwide.As one of the country's largest private employers, we're making health care more affordable and accessible for you and your family.Discover how our economic footprint benefits communities across the U.S: creating...

Read more